August 13, 2018
Dan Kenner, Ph.D., L.Ac. shared research on RBAC in relation to cancer in a presentation titled, “Monitoring changes in blood parameters in cancer patients taking an immune modulator.”
In Japan, Tumor Dormancy Therapy is a concept that is gaining traction. It’s therapeutic objective is to maintain quality of life while prolonging life. According to Dr. Kenner, RBAC addresses 4 factors that promote cancer development –Antioxidant, Anti-inflammatory, Normoglycemiant and Immune Boosting. Cell line culture studies show that NK cell activation by RBAC helps fight cancer. His findings showed that RBAC increases the activity of NK cells as much as 400% and the number of T cells by 200%. Retailers in attendance were seriously impressed with the case studies. Ron Shanker, store manager for Tunies, a natural grocer and vitamin market catering to an older, high-end audience is confident his customers will respond well to it. "The potential is still yet to be known. Beyond the impact it's showing on cancer by rebuilding cells in the body that fight it, the studies on Alzheimer’s and dementia are very promising. My mother, who is a cancer survivor, is already taking it."
Comments will be approved before showing up.
November 05, 2018
July 14, 2018
February 23, 2018
DAIWA HEALTH DEVELOPMENT
Buy 3 bottles of the same product and Get 1 FREE plus FREE shipping.